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Effect of Atropine-Dobutamine Stress Test on Left Ventricular
Echocardiographic Parameters in Untrained Warmblood Horses
Charlotte F. Sandersen, Johanne Detilleux, Brieuc de Moffarts, Gunther Van Loon, and He´le`ne Amory
The aim of this study was to investigate the effect of combined atropine low-dose dobutamine stress test on left ventricular
parameters in adult warmblood horses, to establish a potential protocol for pharmacological stress echocardiography. Seven
healthy untrained warmblood horses aged 9 to 22 years were used. Heart rate (HR) and left ventricular B- and M-mode
dimensions were recorded at baseline and during stress testing with 35 mg/kg atropine IV followed by incremental dobutamine
infusion of 2 to 6 mg/kg/min. HR increased significantly (P , .05) during the pharmacological challenge, and a maximal HR
of 156.6 6 12.5 bpm was reached at maximal dobutamine infusion rate. Systolic and diastolic interventricular septum
thickness, systolic and diastolic left ventricular free wall thickness, and fractional shortening increased significantly and
reached a maximum at the highest infusion rate (mean 6 SD: 4.51 6 0.27 versus 5.65 6 0.31 cm, 2.89 6 0.19 versus 3.78 6
0.10 cm, 3.72 6 0.34 versus 4.77 6 0.18 cm, 2.44 6 0.28 versus 3.11 6 0.34 cm, 34.98 6 3.82 versus 50.56 6 3.42%,
respectively). Systolic and diastolic left ventricular internal diameter decreased significantly during dobutamine infusion. Left
ventricular external and internal area were significantly lower at a dobutamine infusion rate of 2 mg/kg/min but no further
decrease was observed during the subsequent steps. Systolic and diastolic myocardial area was significantly lower after the
administration of dobutamine but not significantly different during dobutamine infusion, when compared to baseline values.
This pharmacological stress test induced significant changes in left ventricular echocardiographic parameters in adult
warmblood horses. Additional research should evaluate the value of this stress test in horses suffering from cardiac disease.
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C ardiovascular disease is the 3rd most commonlydiagnosed cause of poor performance in horses,
after diseases of the musculoskeletal and respiratory
systems.1 Most frequently, cardiovascular problems
associated with poor performance (eg, cardiac arrhyth-
mias, cardiac murmurs) are detected at rest, but
occasionally cardiac disease may be subclinical or not
obvious at rest and therefore may go undiagnosed.2
Such is the case in exercise-induced myocardial dysfunc-
tion, which should be suspected in horses with poor
performance in which no other cause of exercise
intolerance is identified.2 In these horses, stress echo-
cardiography may be of diagnostic value.
Exercise stress echocardiography in horses consists of
an echocardiographic examination performed before
and immediately after a near-maximal to maximal
treadmill test.2 Equine exercise stress echocardiography
is hampered by technical difficulties, such as the fast
decline in heart rate (HR) immediately after the end of
the exercise and the restlessness of the horses when the
treadmill stops.3,4 To overcome these problems, dobuta-
mine stress echocardiography has been investigated in
horses.5 Although chronotropic and inotropic changes
induced by dobutamine at an infusion rate of 50 mg/kg/
min appeared to be similar to those induced by exercise,
the authors of this study did not recommend the use of
dobutamine as a cardiac stressor in the horse because of
its cardiomyotoxic and arrhythmogenic effects.5
An alternative pharmacological stress, which consists
of premedication with 50 mg/kg atropine IV followed by
an incremental challenge of low-dose dobutamine, has
recently been described.6 It allows a reduction in the
required dobutamine dosage by almost a factor of ten to
obtain a cardiac stimulation comparable to that
achieved using high dosages of dobutamine alone
without inducing adverse effects such as cardiac
arrhythmias, trembling, coughing, and restlessness.5,6
The aim of the study was to test the feasibility of this
pharmacological stress protocol and the effect of an
atropine and low-dose dobutamine stress test on left
ventricular echocardiographic parameters in untrained
warmblood horses.
Material and Methods
Seven healthy untrained warmblood horses ranging from 9 to
22 years old (18.5 6 6.0 years, mean 6 SD) and weighing between
440 and 560 kg (506 6 51 kg, mean 6 SD) were used in this study.
They had been selected from the University of Lie`ge Faculty of
Veterinary Medicine teaching herd and were treated according to
the principles of the guidelines of the National Institute of Health
for the care and use of laboratory animals. The protocol was
approved by the ethical committee of the University of Lie`ge.
The horses were considered healthy based on history and
clinical examination and were free of cardiac disease based on
clinical examination, cardiac auscultation, and echocardiographic
examination. Before the protocol, a 16G cathetera was inserted into
the left jugular vein under local anesthesia and in aseptic
conditions.
After baseline echocardiographic recordings of the left ventricle,
a single dose (35 mg/kg) of atropine (crystalline powder in 1%
aqueous solution)b was administered IV. Five minutes after the
injection of atropine, dobutaminec was infused by means of an
infusion pumpd at a rate of 2 mg/kg/min and then increased every
5 minutes in incremental steps of 1 mg/kg/min until an infusion rate
of 6 mg/kg/min was reached. Echocardiographic recordings were
performed 3 minutes after the injection of atropine, as well as
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3 minutes after the onset of each incremental step of dobutamine
infusion.
Echocardiographic examination was performed with a 2.5 MHz
phased array sector transducere. All examinations were recorded on
VHS tape for later analysis. Simultaneously, the integrated apex-
base ECGe was recorded for later calculation of HR. For this
purpose the duration of 3 consecutive RR intervals was measured
and extrapolated to 60 seconds. For each parameter, the mean of 3
cardiac cycles was calculated. Left ventricular internal area (LVIA)
and left ventricular external area (LVEA) were measured at end-
systole (s) and end-diastole (d) from a B-mode echocardiogram of
a standardized right parasternal short axis-view of the left ventricle
at the chordal level.7 From these measurements, the following
indices were calculated:
Myocardial area at end-systole (MYAs)~
LVEAs{ LVIAs,
Myocardial area at end-diastole (MYAd)~
LVEAd{ LVIAd,
Fractional area change (FAC)~
½(LVIAd{ LVIAs) = LVIAd| 100:
From the same view, an M-mode echogram was obtained by
placing the M-mode cursor across the left ventricle so that the
interventricular septum and the left ventricular free wall were
intersected at right angles.7 The following measurements were made
from this M-mode echogram at end-systole (s) and end-diastole (d):
interventricular septal thickness (IVS), left ventricular internal
diameter (LVID), and left ventricular free wall thickness (LVFW).
These parameters were used for the calculation of the following
index:
Fractional shortening (FS)~
½(LVIDd{ LVIDs) = LVIDd| 100:
During the procedure, ECG was monitored on a separate machinef
for the detection of arrhythmias.
Each variable was analyzed separately with a repeated measures
model with an auto-regressive variance-covariance matrix for the
repeated measuresg. Least-square means were computed for each
dose. Differences were considered significant at P , .05. The
repeated mixed model included the fixed group and dose effects
and the random animal and time effects. The autoregressive AR(1)
covariance structure among repeated measurements gave the best
fit, as measured by the largest Akaike and Schwarz values.
Results
All horses tolerated atropine and dobutamine admin-
istration without any adverse reactions. None of the
horses developed cardiac arrhythmias during or after the
pharmacological stress test.
Mean HR increased significantly after the injection of
atropine (Table 1). Mean HR at dobutamine infusion
rates of 2 to 6 mg/kg/min were significantly higher than
after the administration of atropine. Mean HR obtained
at dobutamine infusion rates of 5 and 6 mg/kg/min were
significantly higher than at infusion rates of 2 mg/kg/min
and mean HR obtained at an infusion rate of 6 mg/kg/
min was significantly higher than at 3 mg/kg/min. A
maximal HR of 156.6 6 12.5 bpm (mean 6 SD) was
reached at the rate of 6 mg/kg/min. Results of B-mode
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LVIAs, LVIAd, and LVEAs at dobutamine infusion
rates from 2 to 6 mg/kg/min were significantly lower
compared to baseline values and compared to values
obtained after the administration of atropine. Further-
more, LVIAs was significantly lower at a dobutamine
infusion rate of 5 mg/kg/min than at an infusion rate of
2 mg/kg/min. At all dobutamine infusion rates, mean
LVEAd was significantly lower than at baseline, but
only values obtained at 2, 5, and 6 mg/kg/min of
dobutamine infusion were significantly lower than
values obtained after the administration of atropine.
LVIAd and LVEAs were lowest at an infusion rate of
4 mg/kg/min with mean values of 46.8 6 8.6 cm2 and
150.1 6 7.6 cm2, respectively, compared to 75.2 6
7.9 cm2 and 172.6 6 9.5 cm2, respectively, at baseline.
LVIAs was lowest at an infusion rate of 5 mg/kg/min
with a mean value of 18.46 2.2 cm2 compared to a mean
value of 32.5 6 3.9 cm2 obtained at baseline. LVEAd
was lowest at an infusion rate of 6 mg/kg/min with
a mean value of 180.9 6 8.7 cm2 compared to mean
value of 209.9 6 8.3 cm2 at baseline.
Mean MYAs and mean MYAd were significantly
lower after the administration of atropine than at
baseline, but there were no significant differences
between mean values obtained at all steps of dobuta-
mine infusion and mean values obtained at baseline.
Mean values of MYAd at all steps of dobutamine
infusion were significantly higher than values obtained
after administration of atropine.
FAC was highest at a dobutamine infusion rate of
5 mg/kg/min with a mean value of 63.4 6 6.3%
compared to 56.2 6 8.6% obtained at baseline. At this
step, it was significantly higher than mean values
obtained at baseline, mean values obtained after the
administration of atropine, and mean values obtained at
dobutamine infusion rates of 2 and 4 mg/kg/min. The
mean value of FAC obtained at a dobutamine infusion
rate of 6 mg/mg/min was significantly different from
mean values obtained after the administration of
atropine and mean values obtained at an infusion rate
of 2 mg/kg/min.
Results of M-mode measurements of the pharmaco-
logical stress test are given in Table 2. Mean LVIDd and
mean LVIDs were significantly lower at all steps of
pharmacological challenge than mean values at baseline.
Furthermore, mean LVIDd and mean LVIDs obtained
at all steps of dobutamine infusion were significantly
lower than mean values obtained after the administra-
tion of atropine, with the exception of LVIDd at 6 mg/
kg/min, which was not significantly different from mean
values obtained after the administration of atropine.
The lowest mean value of LVIDd of 8.90 6 0.43 cm was
obtained at a dobutamine infusion rate of 3 mg/kg/min,
compared to a mean value of 10.80 6 0.69 cm
obtained at baseline. The lowest mean value of LVIDs
of 4.65 6 0.15 cm was obtained at a dobutamine
infusion rate of 6 mg/kg/min, compared to a mean value
of 7.02 6 0.65 cm obtained at baseline. Mean LVIDs at
dobutamine infusion rates of 3 and 5 mg/kg/min were
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Mean IVSd was significantly higher at all rates of
dobutamine infusion than mean values obtained at
baseline. Furthermore, mean values obtained at 3, 5,
and 6 mg/kg/min were significantly higher than mean
values obtained at an infusion rate of 2 mg/kg/min and
mean values obtained at 5 and 6 mg/kg/min were
significantly higher than at 4 mg/kg/min. The highest
mean value of 3.78 6 0.10 cm was obtained at an
infusion rate of 6 mg/kg/min, compared to 2.89 6
0.19 cm obtained at baseline.
Mean IVSs was significantly higher at all rates of
pharmacological challenge than mean values obtained at
baseline. Mean IVSs was significantly higher at dobu-
tamine infusion rates of 3 to 6 mg/kg/min than mean
values obtained at 2 mg/kg/min. Furthermore, mean
values obtained at 6 mg/kg/min were significantly higher
than mean values obtained at an infusion rate of 3 mg/
kg/min. The highest IVSs mean value of 5.65 6 0.31 cm
was obtained at a dobutamine infusion rate of 6 mg/kg/
min, compared to 4.51 6 0.27 cm obtained at baseline.
Mean LVFWd and mean LWFWs obtained at all
rates of dobutamine infusion were significantly higher
than those obtained at baseline or after the administra-
tion of atropine. Mean LVFWd obtained at dobutamine
infusion rates of 3 and 6 of mg/kg/min were significantly
higher than those obtained at an infusion rate of 2 mg/
kg/min. Furthermore, the mean value obtained at a rate
of 6 mg/kg/min was higher than at rates of 4 and 5 mg/kg/
min.
Mean LVFWs values obtained at dobutamine in-
fusion rates of 3, 5, and 6 mg/kg/min were significantly
higher than those obtained at an infusion rate of 2 mg/
kg/min. Furthermore, the mean value obtained at a rate
6 mg/kg/min was higher than that obtained at rates of 3,
4, and 5 mg/kg/min. The highest mean values for
LVFWd and LVFWs of 3.11 6 0.34 cm and 4.77 6
0.18 cm, respectively, were obtained at an infusion rate
of 6 mg/kg/min.
Mean values of FS at all rates of dobutamine infusion
were significantly higher than at baseline or after the
administration of atropine. Mean values obtained at 4,
5, and 6 mg/kg/min of dobutamine infusion were
significantly higher than at 2 mg/kg/min. Mean values
obtained at 6 mg/kg/min of dobutamine infusion were
significantly higher than at 3 mg/kg/min. Mean FS was
highest at 6 mg/kg/min with a value of 50.56 6 3.42%.
Discussion
The pharmacological stress test with atropine and
low-dose dobutamine used in the present study was well
tolerated in all horses. In contrast to high-dose
dobutamine infusion,5 no cardiac arrhythmias or ad-
verse reactions such as restlessness were observed during
or after the pharmacological stress test. These findings
confirm an earlier study demonstrating that premedica-
tion with atropine allows reduction of dobutamine
dosage almost 10-fold6, reaching HR comparable to
those obtained after high doses of dobutamine alone.5
However, in contrast to the previously reported atro-
pine/low-dose dobutamine protocol6 atropine was used
at a dosage of 35 mg/kg instead of 50 mg/kg to decrease
the risk of abdominal discomfort. Although in the
previous study using atropine at a dosage of 50 mg/kg
did not result in abdominal discomfort, other studies
reported abdominal discomfort after even lower doses of
atropine.8 One study reported abdominal pain in 1 out
of 5 ponies that had received 44 mg/kg of atropine IV.
Another study described signs of colic in 4 of 6 horses
that received cumulative doses of 11 to 22 mg of
atropine as topical treatment into the ventral conjunc-
tival sac and in 1 of 6 horses that received as little as
3 mg of atropine as a subconjunctival injection.9 These
data indicate that abdominal discomfort may be induced
in horses by much lower doses of atropine than the doses
used in the pharmacological stress test. The aim was to
maximally reduce the risk of abdominal discomfort
while still reaching maximal HR that are similar to those
observed in the previous study. The reduced dose of
atropine premedication led to a slightly lower mean
maximal HR than in the previous study (157 6 7 versus
168 6 12 bpm). However, in the previous study, young
Shetland ponies were tested, and their response to
atropine and dobutamine might be different than in
older warmblood horses.
The ability of the dobutamine stress test to detect
myocardial ischemia is dependent on an adequate
increase in myocardial oxygen consumption, which is
directly related to the HR achieved during stress.10
Achievement of a high HR seems to be essential for
the ability of the stress test to detect cardiac dysfunc-
tion.5 In the study of Frye et al5, mean postexercise HR
reached 160 bpm, whereas in the studies of Marr et al3
and Sampson et al11, mean postexercise HR at the time
of exercise stress echocardiography was 97 bpm and
112 bpm, respectively. In horses, HR declines rapidly
within the first minute after exercise,12,13 which makes
postexercise echocardiographic examination at high HR
difficult. The protocol of the present study seems to be
a good alternative to exercise stress echocardiography
and to high-dose dobutamine stress echocardiography,
as it allows performance of echocardiography at high
HR and avoids adverse effects of high doses of
dobutamine. In human medicine, the target HR of
stress echocardiography is 85% of the age-predicted
maximal HR,14,15 which would correspond to 187–
204 bpm in these horses. Although the mean maximal
HR achieved in the present study was below this value,
the mean maximal HR was still higher than those that
can be routinely obtained in postexercise stress echo-
cardiography. Furthermore, in horses as well as in
humans, the maximal HR decreases with increasing
age.16 Given the high mean age of the horses of this
study (18.5 years), slightly higher values can be expected
in younger performance horses.
The increase in HR and the decrease in LVIDd
observed in the horses of this study after the adminis-
tration of atropine are in accordance with previous
studies.17 Atropine-induced tachycardia is a consequence
of the inhibition of the predominantly parasympathetic
control of HR in the resting horse.18,19 Increases in HR
decrease preload.20 In the present study, the administra-
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tion of atropine led to a decrease in LVIDd, which is
assumed to reflect preload.21,22,23 Preload is mainly
defined by venous return and atrial activity.22 Because
atropine does not influence venous return,24 the ob-
served decrease LVIDd may have resulted from a re-
duction in diastolic filling time coupled with unchanged
venous return.17
Additionally, reduced venous return seems to be
responsible for the changes observed during the dobu-
tamine infusion. Dobutamine administration resulted in
significant increases in IVSs, IVSd, LVFWs, and
LVFWd and significant decreases in LVIDs and
LVIDd. These results are similar to those obtained in
a study in humans in whom dobutamine combined with
atropine resulted in a gradual decrease in LVIDd and
LVIDs and a gradual increase in LVFWs, LVFWd,
IVSd, and IVSs during increasing pharmacological
stimulation.25 These findings reflect the positive inotro-
pic effect of dobutamine and are in contrast to exercise
stress tests in horses in which the same parameters were
not significantly altered immediately after treadmill
exercise.3,11 During exercise, venous return increases as
mean systemic filling pressure rises because of sympa-
thetic stimulation of the veins and because tensing of
abdominal and other muscles of the body compresses
capacitance vessels.3,26,27 In contrast, the muscular pump
function that leads to increased venous return is missing
during the dobutamine stress test. The finding that the
results of dobutamine stress test are related to decreased
preload is suggested by studies performed in humans, in
whom LVIDd was significantly lower during dobuta-
mine than during physical heart stimulation.28 Further-
more, in humans28 as well as in horses3 LVIDd is
unchanged in the immediate postexercise period, but
decreases thereafter because venous return is no longer
maintained by sympathetic stimulation and the com-
pressive effect of muscles, while vasodilatation of the
peripheral vascular beds continues.
The addition of atropine, a cholinergic antagonist,
potentiates both the positive chronotropic and positive
inotropic effects of dobutamine29 but prolongs the
relative duration of systolic emptying and shortens the
diastolic filling phase of the cardiac cycle.30 The pro-
gressive decrease in left ventricular chamber diameter and
progressive increase in wall thickness during increasing
dobutamine infusion rates demonstrated in the study of
Carstensen et al25 are in accordance with the properties of
the drug and may be explained by a combined effect of
increased contractility, decreased afterload, shortening of
diastole, and a relative reduction in venous return. A
similar mechanism could be responsible for the changes
observed in the present study.
The changes in B-mode parameters obtained in the
present study were in agreement with the changes in the
M-mode parameters and were most significant for the
LVIAs and LVIAd. These parameters also decrease in
humans undergoing dobutamine or dobutamine/atro-
pine stress echocardiography.25 Changes in B-mode
parameters were observed after the administration of
atropine and at a dobutamine infusion rate of 2 mg/kg/
min, whereas no more significant change was observed
in the subsequent infusion rates. Consequently, mea-
surements of B-mode parameters at higher infusion rates
can be omitted.
None of the horses in the study were in training, and
therefore conclusions about their physical fitness or
normal myocardial function cannot be made. However,
the consistency of the response within the group suggests
that these animals are representative of their breed and
fitness. Additional studies using this protocol are
required with animals in training so that recommenda-
tions for detecting myocardial dysfunction can be
identified as a cause of poor performance.
In conclusion, the current pharmacological stress test
induced the most prominent changes in the M-mode
parameters LVID, FS, IVS, and LVFW. The B-mode
parameters changed significantly after atropine adminis-
tration and at a dobutamine infusion rate of 2 mg/kg/min,
whereas there was no significant change in the subsequent
steps of dobutamine infusion. This study reveals that the
combination of atropine and low-dose dobutamine is
a practical method to induce cardiac stimulation in the
horses. It allows examination of the heart at high HR,
which can be difficult to achieve in postexercise
examinations, and decrease the occurrences of dobuta-
mine-induced adverse effects, which can be observed
when high doses of dobutamine are administered.
Footnotes
a Intraflon2, Vygon, Ecouen, France
bAtropine, Sigma, Bornem, Belgium
cDobutrex, Lilly, Brussels, Belgium
dModel 960, Imed, San Diego, CA
eVingmed CFM 800, GE medical systems, Brussels, Belgium
fCardiofax GEM, Nihon-Kondem, Tokyo, Japan
g Proc mixed, SAS/STAT software, SAS Institute Inc, Cary, NC
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